
1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name	CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS (NZ)
Synonyms	CANAURAL

1.2 Uses and uses advised against

Uses EAR DROPS • VETERINARY APPLICATIONS • VETERINARY USE

For the treatment of Otitis externa and dermatosis of bacterial origin in dogs and cats.

Uses advised against Do not use in animals with a perforated eardrum. Do not use concurrently with products known to be Ototoxic. Do not use in animals with known hypersensitivity to the active substance(s) or to the excipient.

Persons with known hypersensitivities to any of the active substance(s) or the excipient in the product should avoid contact with the veterinary medicinal product.

1.3 Details of the supplier of the product

Supplier name	DECHRA VETERINARY PRODUCTS NZ LTD
Address	PO Box 1604, Paraparaumu Beach, 5252, NEW ZEALAND
Telephone	0800 473 838
Email	info.nz@dechra.com
Website	http://www.dechra.co.nz/

1.4 Emergency telephone numbers

Emergency	0800 764 766 (National Poisons Centre NZ)
-----------	---

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

HAZARDOUS ACCORDING TO NZ ENVIRONMENTAL PROTECTION AUTHORITY CRITERIA

Physical Hazards

Not classified as a Physical Hazard

Health Hazards

Toxic to Reproduction: Category 2

Environmental Hazards

Aquatic Toxicity (Chronic): Category 3

2.2 GHS Label elements

Signal word **WARNING**

Pictograms



Hazard statements

H361	Suspected of damaging fertility or the unborn child.
H412	Harmful to aquatic life with long lasting effects.

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS (NZ)

Prevention statements

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P273 Avoid release to the environment.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.

Response statements

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage statements

P405 Store locked up.

Disposal statements

P501 Dispose of contents/container in accordance with relevant regulations.

2.3 Other hazards

Persons with a known allergy to Neomycin B Sulphate may exhibit an allergic response to the product. May cause slight irritation to the skin and eyes.

3. COMPOSITION/ INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content (w/w)
NYSTATIN	1400-61-9	215-749-0	2.06%
DIETHANOLAMINE FUSIDATE	16391-75-6	240-442-3	0.5%
NEOMYCIN B SULPHATE	28002-70-2	248-770-9	0.5%
PREDNISOLONE	50-24-8	200-021-7	0.25%
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder

4. FIRST AID MEASURES

4.1 Description of first aid measures

Eye If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.

Inhalation If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

Skin If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.

Ingestion For advice, contact the National Poisons Centre on 0800 764 766 (0800 POISON) or +643 479 7248 or a doctor (at once). If swallowed, do not induce vomiting. Rinse mouth out with water and give plenty of water to drink.

First aid facilities Eye wash facilities and a hand wash basin are recommended.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve carbon oxides, nitrogen oxides, chlorides and hydrocarbons when heated to decomposition.

5.3 Advice for firefighters

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS (NZ)

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

6.2 Environmental precautions

Prevent product from entering drains and waterways.

6.3 Methods of cleaning up

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well marked area, removed from incompatible substances, foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 25°C.

7.3 Specific end uses

No information provided.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

Exposure standards

No exposure standards have been entered for this product.

Biological limits

No biological limit values have been entered for this product.

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas.

PPE

Eye / Face	Wear splash-proof goggles.
Hands	Wear PVC or rubber gloves.
Body	Wear coveralls.
Respiratory	Where an inhalation risk exists, wear a Type A (Organic vapour) respirator.



9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance VISCOUS YELLOW LIQUID

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS (NZ)

9.1 Information on basic physical and chemical properties

Odour	SLIGHT ODOUR
Flammability	NON FLAMMABLE
Flash point	NOT RELEVANT
Boiling point	NOT AVAILABLE
Melting point	NOT AVAILABLE
Evaporation rate	NOT AVAILABLE
pH	NOT AVAILABLE
Vapour density	NOT AVAILABLE
Relative density	NOT AVAILABLE
Solubility (water)	NOT AVAILABLE
Vapour pressure	NOT AVAILABLE
Upper explosion limit	NOT RELEVANT
Lower explosion limit	NOT RELEVANT
Partition coefficient	NOT AVAILABLE
Autoignition temperature	NOT AVAILABLE
Decomposition temperature	NOT AVAILABLE
Viscosity	NOT AVAILABLE
Explosive properties	NOT AVAILABLE
Oxidising properties	NOT AVAILABLE
Odour threshold	NOT AVAILABLE

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

10.2 Chemical stability

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Polymerization is not expected to occur.

10.4 Conditions to avoid

Avoid heat, sparks, open flames and other ignition sources.

10.5 Incompatible materials

Incompatible with oxidising agents (e.g. hypochlorites), acids (e.g. nitric acid) and alkalis (e.g. sodium hydroxide).

10.6 Hazardous decomposition products

May evolve carbon oxides, nitrogen oxides, chlorides and hydrocarbons when heated to decomposition.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity May be harmful. This product is used in veterinary applications. Use safe work practices to avoid eye contact, prolonged skin contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.

Information available for the ingredients:

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
NYSTATIN	8000 mg/kg (mouse)	--	--
NEOMYCIN B SULPHATE	> 5 g/kg (mouse)	--	--
PREDNISOLONE	1680 mg/kg (mouse)	--	--

Skin Contact may result in irritation, redness, pain and rash.
Eye Contact may result in irritation, lacrimation, pain and redness.
Sensitisation Not classified as causing skin or respiratory sensitisation.
Mutagenicity Not classified as a mutagen.
Carcinogenicity Not classified as a carcinogen.

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS (NZ)

Reproductive	Suspected of damaging fertility or the unborn child.
STOT - single exposure	Not classified as causing organ damage from single exposure. However, high level exposure may result in headache, nausea and respiratory tract irritation.
STOT - repeated exposure	Not classified as causing organ damage from repeated exposure.
Aspiration	Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Harmful to aquatic life with long lasting effects.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.

12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No information provided.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal	Return to manufacturer/supplier where possible. For small amounts, bury in approved landfill site. Contact the manufacturer/supplier for additional information (if required).
Legislation	Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD ACCORDING TO LAND TRANSPORT RULE: DANGEROUS GOODS 2005; NZS 5433:2012, UN, IMDG OR IATA

	LAND TRANSPORT (NZS 5433)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.

14.5 Environmental hazards

Not a Marine Pollutant.

14.6 Special precautions for user

Hazchem code None allocated.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Approval code	HSR100757
Group standard	Veterinary Medicines (Limited Pack Size, Finished Dose) Group Standard 2020
ACVM Number	A002777

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS (NZ)

Inventory listings **AUSTRALIA: AIC (Australian Inventory of Industrial Chemicals)**
All components are listed on AIC, or are exempt.
NEW ZEALAND: NZIoC (New Zealand Inventory of Chemicals)
All components are listed on the NZIoC inventory, or are exempt.

16. OTHER INFORMATION

Additional information **WORKPLACE CONTROLS AND PRACTICES:** Unless a less toxic chemical can be substituted for a hazardous substance, **ENGINEERING CONTROLS** are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

RESPIRATORS: In general the use of respirators should be limited and engineering controls employed to avoid exposure. If respiratory equipment must be worn ensure correct respirator selection and training is undertaken. Remember that some respirators may be extremely uncomfortable when used for long periods. The use of air powered or air supplied respirators should be considered where prolonged or repeated use is necessary.

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:
The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:
It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

Abbreviations	ACGIH	American Conference of Governmental Industrial Hygienists
	CAS #	Chemical Abstract Service number - used to uniquely identify chemical compounds
	CCID	Chemical Classification and Information Database (HSNO)
	CNS	Central Nervous System
	EC No.	EC No - European Community Number
	EMS	Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous Goods)
	EPA	Environmental Protection Authority [New Zealand]
	GHS	Globally Harmonized System
	HSNO	Hazardous Substances and New Organisms
	IARC	International Agency for Research on Cancer
	LC50	Lethal Concentration, 50% / Median Lethal Concentration
	LD50	Lethal Dose, 50% / Median Lethal Dose
	mg/m ³	Milligrams per Cubic Metre
	OEL	Occupational Exposure Limit
	pH	relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly alkaline).
	ppm	Parts Per Million
	STEL	Short-Term Exposure Limit
	STOT-RE	Specific target organ toxicity (repeated exposure)
	STOT-SE	Specific target organ toxicity (single exposure)
	TLV	Threshold Limit Value
	TWA	Time Weighted Average

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS (NZ)

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

Prepared by

Risk Management Technologies
5 Ventnor Ave, West Perth
Western Australia 6005
Phone: +61 8 9322 1711
Fax: +61 8 9322 1794
Email: info@rmt.com.au
Web: www.rmtglobal.com

[End of SDS]